Author name: Leonardo Arias

Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.

The latest agreement includes higher fees for overseas firms, hiring transparency requirements and greater use of real-world evidence.

NYU Langone Health and Dana-Farber Cancer Institute built an oncology decision support tool to guide clinicians through treatment. Now, the institutions are commercializing the product so other health systems can use it too.

News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.

Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.

Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.

Patients treated with Tenax Therapeutics’ heart failure drug TNX-103 did not show significantly better functional performance—though Leerink analysts found biomarker improvements and subgroup analyses in elderly and more severe patients “very encouraging.”

BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.

After launching in April, Hunter syndrome drug Avlayah surprised analysts with a strong first quarter, as patients rush to get access to Denali Therapeutics’ new option.